AN2 Therapeutics (ANTX) Stock Forecast for 2023 – 2026. Sell or Buy?
Last update: September 30, 2023 (11:07)
Sector: HealthcareThe share price of AN2 Therapeutics, Inc. (ANTX) now
50/200 Day Moving Average: $9.58 / $9.46
This figure corresponds to the Average Price over the previous 50/200 days. For AN2 Therapeutics stocks, the 50-day moving average is the support level today.
For AN2 Therapeutics stocks, the 200-day moving average is the support level today.
Are you interested in AN2 Therapeutics, Inc. stocks and want to buy them, or are they already in your portfolio? If yes, then on this page you will find useful information about the dynamics of the AN2 Therapeutics stock price in 2023, 2024, 2025, 2026, 2027. How much will one AN2 Therapeutics share be worth in 2023 - 2027?
When should I take profit in AN2 Therapeutics stock? When should I record a loss on AN2 Therapeutics stock? What are analysts' forecasts for AN2 Therapeutics stock? What is the future of AN2 Therapeutics stock? We forecast AN2 Therapeutics stock performance using neural networks based on historical data on AN2 Therapeutics stocks. Also, when forecasting, technical analysis tools are used, world geopolitical and news factors are taken into account.
AN2 Therapeutics stock prediction results are shown below and presented in the form of graphs, tables and text information, divided into time intervals. (Next month, 2023, 2024, 2025, 2026 and 2027) The final quotes of the instrument at the close of the previous trading day are a signal to adjust the forecasts for AN2 Therapeutics shares. This happens once a day.
Historical and forecast chart of AN2 Therapeutics stock
The chart below shows the historical price of AN2 Therapeutics stock and a prediction chart for the next month. For convenience, prices are divided by color. Forecast prices include: Optimistic Forecast, Pessimistic Forecast, and Weighted Average Best Forecast. Detailed values for the AN2 Therapeutics stock price can be found in the table below.
Long-term forecasts by years.
AN2 Therapeutics daily forecast for a month
| Date | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Oct 02 | 16.21 | 15.87 | 16.47 | 3.78 |
| Oct 03 | 16.10 | 15.91 | 16.31 | 2.49 |
| Oct 04 | 16.27 | 16.13 | 16.62 | 2.99 |
| Oct 05 | 16.02 | 15.91 | 16.35 | 2.77 |
| Oct 06 | 15.84 | 15.61 | 15.93 | 2.03 |
| Oct 07 | 16.11 | 15.83 | 16.41 | 3.65 |
| Oct 08 | 15.90 | 15.70 | 16.15 | 2.87 |
| Oct 09 | 16.02 | 15.67 | 16.24 | 3.64 |
| Oct 10 | 16.34 | 16.24 | 16.55 | 1.90 |
| Oct 11 | 16.19 | 16.03 | 16.41 | 2.37 |
| Oct 12 | 15.97 | 15.87 | 16.29 | 2.66 |
| Oct 13 | 15.95 | 15.79 | 16.12 | 2.10 |
| Oct 14 | 15.97 | 15.77 | 16.16 | 2.46 |
| Oct 15 | 15.91 | 15.67 | 16.14 | 3.04 |
| Oct 16 | 16.23 | 15.96 | 16.55 | 3.71 |
| Oct 17 | 16.26 | 16.02 | 16.37 | 2.19 |
| Oct 18 | 16.48 | 16.33 | 16.59 | 1.61 |
| Oct 19 | 16.55 | 16.44 | 16.78 | 2.07 |
| Oct 20 | 16.54 | 16.37 | 16.88 | 3.14 |
| Oct 21 | 16.50 | 16.31 | 16.67 | 2.16 |
| Oct 22 | 16.45 | 16.27 | 16.68 | 2.48 |
| Oct 23 | 16.55 | 16.36 | 16.79 | 2.65 |
| Oct 24 | 16.65 | 16.52 | 16.89 | 2.20 |
| Oct 25 | 16.97 | 16.66 | 17.28 | 3.74 |
| Oct 26 | 17.40 | 17.24 | 17.57 | 1.88 |
| Oct 27 | 17.74 | 17.41 | 18.02 | 3.49 |
| Oct 28 | 17.41 | 17.15 | 17.61 | 2.71 |
| Oct 29 | 17.19 | 16.82 | 17.37 | 3.26 |
| Oct 30 | 16.86 | 16.65 | 16.97 | 1.94 |
| Oct 31 | 16.92 | 16.68 | 17.16 | 2.88 |
AN2 Therapeutics Daily Price Targets
AN2 Therapeutics Stock Forecast 10-02-2023.
Forecast target price for 10-02-2023: $16.21.
Positive dynamics for AN2 Therapeutics shares will prevail with possible volatility of 3.640%.
Pessimistic target level: 15.87
Optimistic target level: 16.47
AN2 Therapeutics Stock Forecast 10-03-2023.
Forecast target price for 10-03-2023: $16.10.
Negative dynamics for AN2 Therapeutics shares will prevail with possible volatility of 2.426%.
Pessimistic target level: 15.91
Optimistic target level: 16.31
AN2 Therapeutics Stock Forecast 10-04-2023.
Forecast target price for 10-04-2023: $16.27.
Positive dynamics for AN2 Therapeutics shares will prevail with possible volatility of 2.907%.
Pessimistic target level: 16.13
Optimistic target level: 16.62
AN2 Therapeutics Stock Forecast 10-05-2023.
Forecast target price for 10-05-2023: $16.02.
Negative dynamics for AN2 Therapeutics shares will prevail with possible volatility of 2.697%.
Pessimistic target level: 15.91
Optimistic target level: 16.35
AN2 Therapeutics Stock Forecast 10-06-2023.
Forecast target price for 10-06-2023: $15.84.
Negative dynamics for AN2 Therapeutics shares will prevail with possible volatility of 1.987%.
Pessimistic target level: 15.61
Optimistic target level: 15.93
AN2 Therapeutics Stock Forecast 10-07-2023.
Forecast target price for 10-07-2023: $16.11.
Positive dynamics for AN2 Therapeutics shares will prevail with possible volatility of 3.526%.
Pessimistic target level: 15.83
Optimistic target level: 16.41
ANTX (ANTX) Monthly Stock Prediction for 2023
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Oct. | 15.91 | 15.41 | 16.71 | 7.77 |
| Nov. | 16.90 | 15.97 | 17.79 | 10.26 |
| Dec. | 16.86 | 16.34 | 17.37 | 5.98 |
AN2 Therapeutics forecast for this year
AN2 Therapeutics Stock Prediction for Oct 2023
An downtrend is forecast for this month with an optimal target price of $15.9089. Pessimistic: $15.41. Optimistic: $16.71
AN2 Therapeutics Stock Prediction for Nov 2023
An uptrend is forecast for this month with an optimal target price of $16.9016. Pessimistic: $15.97. Optimistic: $17.79
AN2 Therapeutics Stock Prediction for Dec 2023
An downtrend is forecast for this month with an optimal target price of $16.8611. Pessimistic: $16.34. Optimistic: $17.37
AN2 Therapeutics (ANTX) Monthly Stock Prediction for 2024
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 16.21 | 15.21 | 16.52 | 7.93 |
| Feb | 15.94 | 15.48 | 16.26 | 4.78 |
| Mar | 16.96 | 15.93 | 17.38 | 8.35 |
| Apr | 16.35 | 15.38 | 17.29 | 11.04 |
| May | 16.06 | 15.36 | 16.35 | 6.05 |
| Jun | 16.63 | 15.70 | 17.15 | 8.46 |
| Jul | 17.00 | 16.31 | 17.89 | 8.82 |
| Aug | 17.31 | 16.37 | 17.66 | 7.29 |
| Sep | 16.18 | 15.83 | 16.79 | 5.71 |
| Oct | 16.41 | 15.51 | 17.13 | 9.50 |
| Nov | 15.79 | 15.05 | 16.36 | 8.03 |
| Dec | 16.78 | 16.39 | 17.44 | 6.00 |
AN2 Therapeutics (ANTX) Monthly Stock Prediction for 2025
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 16.90 | 16.12 | 17.21 | 6.36 |
| Mar | 17.36 | 16.58 | 17.92 | 7.44 |
| Mar | 17.17 | 16.14 | 17.92 | 9.96 |
| Apr | 17.67 | 16.57 | 18.04 | 8.15 |
| May | 17.83 | 17.20 | 18.63 | 7.66 |
| Jun | 16.92 | 16.35 | 17.66 | 7.43 |
| Jul | 16.27 | 15.36 | 17.13 | 10.33 |
| Aug | 16.67 | 15.87 | 17.58 | 9.71 |
| Sep | 17.30 | 16.59 | 18.38 | 9.71 |
| Oct | 17.99 | 17.37 | 18.65 | 6.87 |
| Nov | 18.02 | 16.86 | 18.75 | 10.07 |
| Dec | 19.30 | 18.81 | 20.30 | 7.38 |
AN2 Therapeutics (ANTX) Monthly Stock Prediction for 2026
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 17.85 | 16.98 | 18.55 | 8.47 |
| Mar | 16.51 | 16.06 | 17.51 | 8.30 |
| Mar | 17.07 | 16.15 | 17.66 | 8.58 |
| Apr | 16.02 | 15.37 | 16.48 | 6.77 |
| May | 16.46 | 15.79 | 17.20 | 8.19 |
| Jun | 17.20 | 16.47 | 18.04 | 8.70 |
| Jul | 18.50 | 17.33 | 19.48 | 11.02 |
| Aug | 17.85 | 17.12 | 18.94 | 9.58 |
| Sep | 18.68 | 17.99 | 19.13 | 5.94 |
| Oct | 18.89 | 17.95 | 19.33 | 7.12 |
| Nov | 20.35 | 19.87 | 21.17 | 6.15 |
| Dec | 21.02 | 19.96 | 21.43 | 6.83 |
AN2 Therapeutics (ANTX) Monthly Stock Prediction for 2027
| Month | Target | Pes. | Opt. | Vol., % |
|---|---|---|---|---|
| Jan | 20.23 | 19.81 | 21.12 | 6.21 |
| Mar | 19.71 | 19.10 | 20.91 | 8.67 |
| Mar | 18.97 | 17.76 | 20.17 | 11.96 |
| Apr | 19.53 | 18.99 | 20.47 | 7.25 |
| May | 20.28 | 19.33 | 20.92 | 7.60 |
| Jun | 20.84 | 19.87 | 21.44 | 7.31 |
| Jul | 20.55 | 20.09 | 20.93 | 4.01 |
| Aug | 20.13 | 19.18 | 20.90 | 8.24 |
| Sep | 21.01 | 20.56 | 21.65 | 5.05 |
| Oct | 22.29 | 21.47 | 23.22 | 7.53 |
| Nov | 22.24 | 20.92 | 23.46 | 10.84 |
| Dec | 23.69 | 23.24 | 24.15 | 3.77 |
AN2 Therapeutics information and performance
AN2 is developing treatments for rare, chronic, and serious infectious diseases. Its initial product candidate is epetraborole, a once-daily oral drug that aims to treat chronic nontuberculous mycobacterial lung disease.
The biotech is the second company to open for trading in March. The first was Akanda (ticker: AKAN), a medical-cannabis company, which listed its shares on March 15, soaring 163% in its debut. Akanda stock is down about 18% from the $10.50 first-day closing price but still up 116% from the $4 IPO price.
1800 EL CAMINO REAL, SUITE D, MENLO PARK, CA, US
Market capitalization of the AN2 Therapeutics, Inc. is the total market value of all issued shares of a company. It is calculated by the formula multiplying the number of ANTX shares in the company outstanding by the market price of one share.
EBITDA of AN2 Therapeutics is earnings before interest, income tax and depreciation of assets.
P/E ratio (price to earnings) - shows the ratio between the price of a share and the company's profit
Price/earnings to growth
Dividend Per Share is a financial indicator equal to the ratio of the company's net profit available for distribution to the annual average of ordinary shares.
Dividend yield is a ratio that shows how much a company pays in dividends each year at the stock price.
EPS shows how much of the net profit is accounted for by the common share.
Trailing P/E depends on what has already been done. It uses the current share price and divides it by the total earnings per share for the last 12 months.
Forward P/E uses projections of future earnings instead of final numbers.
Enterprise Value (EV) /Revenue
The EV / EBITDA ratio shows the ratio of the cost (EV) to its profit before tax, interest and amortization (EBITDA).
Number of issued ordinary shares
Number of freely tradable shares
Shares Short Prior Month - the number of shares in short positions in the last month.
